

AMENDMENTS TO THE CLAIMS

Please amend the claims so that they read as follows:

Claims 1-28 (Canceled)

29. (Previously Presented): A method for administering salmon calcitonin to an animal in need thereof, the method comprising administering orally to the animal a composition comprising:

- (a) N-(5-chlorosalicyloyl)-8-aminocaprylic acid, wherein N-(5-chlorosalicyloyl)-8-aminocaprylic acid comprises at least about 96% by weight of the disodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid; and
- (b) salmon calcitonin.

Claims 30-61 (Canceled)

62. (Currently Amended): A pharmaceutical composition comprising (a) at least about 50% by weight of ~~the disodium salt of claim 59~~ a disodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid, based upon 100% total weight of the ~~delivery agent~~ N-(5-chlorosalicyloyl)-8-aminocaprylic acid and salts thereof in the composition, and (b) at least one active agent.

63. (Currently Amended): The pharmaceutical composition of claim 62, wherein the composition comprises at least about 90% by weight of the disodium salt, based upon 100% total weight of ~~delivery agent~~ N-(5-chlorosalicyloyl)-8-aminocaprylic acid and salts thereof in the composition.

64. (Previously Presented): The pharmaceutical composition of claim 62, wherein the active agent is selected from the group consisting of growth hormones; human growth hormones; recombinant human growth hormones; bovine growth hormones; porcine growth hormones; growth hormone-releasing hormones;

interferons; α -interferon; β -interferon; γ -interferon; interleukin-1; interleukin-2; insulin; porcine insulin; bovine insulin; human insulin; human recombinant insulin; insulin-like growth factor; IGF-1; heparin; unfractionated heparin; heparinoids; dermatans; chondroitins; low molecular weight heparin; very low molecular weight heparin; ultra low molecular weight heparin; calcitonin; salmon calcitonin; eel calcitonin; human calcitonin; porcine calcitonin; erythropoietin; atrial natriuretic factor; antigens; monoclonal antibodies; somatostatin; protease inhibitors; adrenocorticotropin; gonadotropin releasing hormone; oxytocin; leutinizing-hormone-releasing-hormone; follicle stimulating hormone; glucocerebrosidase; thrombopoietin; filgrastim; prostaglandins; cyclosporin; vasopressin; cromolyn sodium; sodium chromoglycate; disodium chromoglycate; vancomycin; desferrioxamine; parathyroid hormone; fragments of parathyroid hormone; antimicrobials; anti-fungal agents; vitamins; analogs, fragments, mimetics and polyethylene glycol-modified derivatives of these compounds; and any combination thereof.

65. (Previously Presented): The pharmaceutical composition of claim 62, wherein the active agent is calcitonin.

66. (Previously Presented): A dosage unit form comprising:

- (a) the pharmaceutical composition of claim 62; and
- (b)
 - (i) an excipient,
 - (ii) a diluent,
 - (iii) a disintegrant,
 - (iv) a lubricant,
 - (v) a plasticizer,
 - (vi) a colorant,
 - (vii) a dosing vehicle, or
 - (viii) any combination thereof.